Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians

British Journal of Clinical Pharmacology

Volumn 55, Issue 6, 2003, Pages 630-634

  Dalen P ^a   Dahl, Marja Liisa ^a,e   Roh, H K ^a,d   Tybring, G ^a   Eichelbaum, M ^b   Wilkinson, G R ^c   Bertilsson, L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^c VANDERBILT UNIVERSITY   (United States)

^d Inha University Hospital   (South Korea)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2D6; Cytochrome P450; Debrisoquine; Interetchnic differences; Nortriptyline

Indexed keywords

10 HYDROXYNORTRIPTYLINE; 4 HYDROXYDEBRISOQUINE; CYTOCHROME P450 2D6; DEBRISOQUINE; NORTRIPTYLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; FEMALE; GENOTYPE; HUMAN; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RACE DIFFERENCE;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; DEBRISOQUIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; KOREA; MALE; MIDDLE AGED; NORTRIPTYLINE;

EID: 0038127222     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2003.01804.x     Document Type: Article

References (16)

1. Nakamura K, Goto F, Ray WA et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-408.
2. Bertilsson L, Lou YQ, Du YL et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-397.
3. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-459.
4. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in PFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53: 410-418.
5. Roh HK, Dahi ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6: 441-447.
6. Lin KM, Finder E. Neuroleptic dosage for Asians. Am J Psychiatry 1983; 140: 490-491.
7. Lin KM, Poland RE, Lau JK, Rubin RT. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988; 8: 195-201.
8. Lai M, Wang S, Lai M, Lin E, Tse M, Huang J. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995; 58: 264-268.
9. Huang J, Chuang SK, Cheng CL, Lai ML. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin Pharmacol Thor 1999; 65: 402-407.
10. Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981; 30: 189-193.
11. Dalén P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriputyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444-452.
12. Dalén P, Dahl M-L, Eichelbaum M, Bertilsson L, Wilkinson G. Disposition of debrisoqume m Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 1999; 9: 697-706.
13. Yue QY, Zhong ZH, Tybring G et al. Pharmacokinetics of nortriptyline and its 10-hydroxy merabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharm Ther 1998; 64: 384-390.
14. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992; 51: 12-17.
15. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCK amplification. Lancet 1990; 336: 529-532.
16. Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. Steady-state plasma levels of nortripwline and its hydroxylated metabolites in Japanese patients. Impact of CYP2D6 genowpe on the hydroxylation of nortriptyline. J Clin Psychopharmacol 2000; 20: 141-149.